- Cell-based medicines company MaxCyte Group launched a share issue to raise at least £10.0m to fund an acceleration of its growth strategy.

New shares in the company would be issued at 170p each.

MaxCyte said the raising would support an expansion of its cell-therapy pipeline and the formation of clinical and commercial deals.

Story provided by